Abstract:Depression is a heterogeneous disease state characterised by complex alterations in several CNS neurotransmitter and receptor systems. All antidepressants are thought to act by causing postsynaptic adaptive changes (e.g. in transducers or second messengers) within these systems. Thus, the mechanism of action of selective serotonin reuptake inhibitors (SSRIs) cannot simply be explained in terms of inhibition of serotonin (5-hydroxytryptamine) [5-HT] reuptake. Fluvoxamine, sertraline and fluoxetine downregulate central β-adrenoceptors, and all SSRIs are believed to normalise central 5-HT1A- and 5-HT2-receptor density and function in patients with depression.SSRIs are as effective as tricyclic antidepressants in the treatment of depression, but have distinct tolerability advantages — they are not associated with anticholinergic adverse effects, cardiotoxicity, sedation or weight gain. However, gastrointestinal reactions (e.g. nausea, diarrhoea/loose stools, constipation) are relatively common during SSRI therapy. Additionally, in contrast to tricyclic antidepressants, SSRI dosage adjustments appear to be unnecessary in elderly depressed patients. Fluvoxamine has a much shorter elimination half-life than fluoxetine and its active metabolite, norfluoxetine, and therefore a reduced potential for drug interactions. Only small amounts of fluvoxamine and fluoxetine, but large quantities of paroxetine, are secreted in breast milk. Furthermore, genetic polymorphism has not been documented for fluvoxamine metabolism, whereas slow and fast metabolisers of paroxetine, and fast metabolisers of fluoxetine have been identified.SSRIs have a better tolerability profile than tricyclic antidepressants, as indicated by lower mean rank scores for behavioural toxicity. Moreover, SSRIs are associated with a much lower incidence of fatal toxicity than tricyclics, and appear to be relatively safe in overdosage.Thus, SSRIs represent a class of antidepressants with similar efficacy to, but major tolerability advantages over, tricyclic agents. Continued use of and experience with SSRIs will enhance our understanding of the central serotonergic system and may lead to the development of more selective drugs in the future.

The genetics of selective serotonin reuptake inhibitors

Advances in pharmacogenomics of selective serotonin reuptake inhibitors

Pharmacogenetics of selective serotonin reuptake inhibitors (SSRI): A serotonin reuptake transporter (SERT)-based approach

Genetic, epigenetic and posttranscriptional mechanisms for treatment of major depression: the 5-HT1A receptor gene as a paradigm

Serotonergic gene expression and depression: implications for developing novel antidepressants

Pharmacological Differences of Serotonin Reuptake Inhibitors and Possible Clinical Relevance

Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs)

5-Htr1a And 5-Htr2a Genetic Polymorphisms And Ssri Antidepressant Response In Depressive Chinese Patients

The role of 5-HT receptors in depression

Serotonin Transporter Gene Polymorphisms and Selective Serotonin Reuptake Inhibitor Tolerability: Review of Pharmacogenetic Evidence

Effects of serotonin transporter and receptor polymorphisms on depression

Pharmacogenetics of the serotonin transporter

Serotonin transporter polymorphism and response to SSRIs in major depression and relevance to anxiety disorders and substance abuse

The Relationship Between Single Nucleotide Polymorphisms in 5-HT2A Signal Transduction-Related Genes and the Response Efficacy to Selective Serotonin Reuptake Inhibitor Treatments in Chinese Patients with Major Depressive Disorder

Review : Serotonin Transporter and Psychiatric Disorders: Listening to the Gene

The neurobiology of depression—revisiting the serotonin hypothesis. II. Genetic, epigenetic and clinical studies

Looking Beyond the 5-HTTLPR Polymorphism: Genetic and Epigenetic Layers of Regulation Affecting the Serotonin Transporter Gene Expression

Mechanisms of action of selective serotonin reuptake inhibitors in the treatment of psychiatric disorders

Systems Approach to Identify Common Genes and Pathways Associated with Response to Selective Serotonin Reuptake Inhibitors and Major Depression Risk